EUCTR2011-006236-23-PL进行中（未招募）不适用
A Randomized, Double-Blind, Placebo-controlled, Three-arm, Parallel Assignment, Multi-centre, Therapeutic Equivalence Study of Two Tacrolimus 0.1% Topical Ointment Formulations in Adult Patients with Moderate to Severe Atopic Dermatitis.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 650
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or non-pregnant, non-lactating female of any ethnic group, 18 – 70 years of age (both inclusive) at the time of signing the informed consent.
- •2.Patients having atopic dermatitis according to Hanifin and Rajka diagnostic criteria (Appendix I).
- •3.Patients with a grading of moderate to severe AD (i.e. a score of at least 4.5) as defined by the scoring system of Rajka and Langeland (Appendix II).
- •4.Non-immunocompromised adults who have failed to respond adequately to other topical prescription treatments for AD, or when those treatments are not advisable in the opinion of the Investigator.
- •5.Last application of medicated topical agents, intake of systemic antihistamines, intranasal or inhaled corticosteroids (> 1 mg/day) should be minimum 7 days prior to randomization.
- •6.Last application of tacrolimus ointment, intake of systemic corticosteroids and nonsteroidal immunosuppressants should be minimum 3 weeks prior to randomization.
- •7.Both male and female patients of child bearing potential must be practicing adequate contraception and female patients of child-bearing potential must not be pregnant or lactating and must have a negative serum pregnancy test at screening and negative urine pregnancy test at randomization.
- •8.Patient is capable of understanding the purposes and risks of the trial and has given written informed consent, which includes compliance with the study requirements and restrictions listed in the consent form.
- •9.Patient has not taken and agrees not to take any medication or therapy prohibited by the protocol for the entire study period.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 600
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1.Newly diagnosed or Treatment naïve patients.
- •2.Patients with mild (Rajka and Langeland score of < 4.5) or very severe atopic dermatitis that requires systemic therapy.
- •3.Patients in need of undergoing UV treatments for AD.
- •4.Clinically infected atopic dermatitis at the baseline visit.
- •5.Any deermatological condition other than atopic dermatitis as scar/wound/tattoo at the application site or in its close vicinity that in the Investigator's opinion may interfere with the evaluation of the patient's atopic dermatitis
- •6.History of allergy or hypersensitivity to tacrolimus or any of the ointment excipients, pimecrolimus, any macrolides such as clindamycin, erythromycin, azithromycin, clarithyromycin etc.
- •7.History or known case of congenital or acquired immunodeficiencies, which in the Investigator’s opinion would contraindicate the use of immunosuppressants, including but not limited to human immunodeficiency virus (HIV) infection and cancer.
- •8.Patient with a known case of genetic epidermal barrier defect such as Netherton’s syndrome or generalised erythroderma.
- •9.Patients with a known case of Cushing’s syndrome.
- •10. Patients with diagnosed hepatic failure:
- •Serum bilirubin= 1.5 times ULN
- •Serum AST/ALT= 2.5 times ULN
- •11. Abnormal baseline findings considered by the Investigator to indicate conditions that might affect study endpoints.
- •12.Any form of substance abuse (including drug or alcohol abuse), psychiatric disorder or condition which, in the opinion of the Investigator, may invalidate the communication with the Investigator or adversely affect the study outcome.
- •13.Positive urine drug scan at screening visit for drugs likely to cause abuse.
- •14.Last participation in any other clinical study involving investigational medicinal product within 60 days of randomization. However, it is at the sole discretion of the Investigator to enroll eligible patients considering elimination half-life of such study drug of last participation and/or pharmacokinetic profile of such drug molecule of last participation and/or other medical judgement (if any) to justify the subject’s participation.
- •15.Clinically unstable laboratory test results or any other condition that, in the Investigator’s judgment, might increase the risk to the patient or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.
研究者
相似试验
已完成
不适用
To evaluate the Bio equivalence of two Tacrolimus 0.03% topical Ointment formulations in adult patients with moderate to Severe Atopic DermatitisCTRI/2016/03/006735Intas Pharmaceuticals Ltd346
招募中
3 期
A study to evaluate effectiveness of Tacrolimus 0.1% Topical Ointment in the patients of the allergic dermatitis.CTRI/2012/05/002636Accord Healthcare Ltd650
进行中（未招募）
3 期
To understand the safety and outcome of Tacrolimus ointment 0.1% in patients suffering from Atopic dermatitisCTRI/2023/05/052282JAMP Pharma Corporation
已完成
1 期
Bioequivalence Study of Pimecrolimus cream in Atopic dermatitis patientsCTRI/2018/11/016271Encube Ethicals Private Ltd588
尚未招募
不适用
A study for Improving Physiological Function, Psychological, Emotional and Mental Health as well as Wellness in Adult Subjects for a better Quality of Life.CTRI/2022/07/043736Trivedi Global Inc